Risk factor analysis for ceftriaxone-associated liver dysfunction in older patients.

IF 1.2 Q4 PHARMACOLOGY & PHARMACY
Tomohiko Tagashira, Ryoya Odawara, Naohito Suga, Rikako Nakamura, Makoto Tagashira, Kohei Minematsu
{"title":"Risk factor analysis for ceftriaxone-associated liver dysfunction in older patients.","authors":"Tomohiko Tagashira, Ryoya Odawara, Naohito Suga, Rikako Nakamura, Makoto Tagashira, Kohei Minematsu","doi":"10.1186/s40780-026-00554-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Information on ceftriaxone (CTRX)-associated liver dysfunction in older patients remains limited. This study, investigated the risk factors for CTRX-associated liver dysfunction in patients aged ≥65 years.</p><p><strong>Methods: </strong>We conducted a retrospective chart review of the medical records of 105 hospitalized patients aged ≥65 years who received CTRX at Innoshima-Ishikai Hospital. Variables significantly associated with liver dysfunction in univariate analyses were entered into a multivariate logistic regression model to identify independent risk factors. Cutoff values were determined using receiver operating characteristic curve analysis. The incidence of liver dysfunction was compared according to the number of identified risk factors. Fisher's exact test was used for comparisons between groups.</p><p><strong>Results: </strong>In univariate analyses, alanine aminotransferase (ALT) and C-reactive protein (CRP) levels were significantly associated with liver dysfunction (p < 0.05). Multivariate logistic regression identified ALT as an independent risk factor (odds ratio [OR] 1.14; 95% confidence interval [CI]: 1.04-1.24, p = 0.003). CRP was also significantly associated with liver dysfunction, although the effect size was small (OR 1.07; 95% CI: 1.00-1.14, p = 0.043). The optimal cutoff values were 11 U/L for ALT and 5.9 mg/dL for CRP. The incidence of liver dysfunction was 0% in patients with no risk factors, 10.7% in those with elevated ALT only, 8.3% in those with elevated CRP only, and 50% in those with both elevated ALT and CRP. Patients with both risk factors had a significantly higher incidence of liver dysfunction than those in the other groups (p < 0.001).</p><p><strong>Conclusion: </strong>Among patients aged ≥ 65 years, elevated baseline ALT (≥ 11 U/L) and CRP (≥ 5.9 mg/dL) levels were associated with an increased risk of CTRX-associated liver dysfunction. Careful monitoring of liver function during and after CTRX administration is therefore recommended in this population.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":" ","pages":"20"},"PeriodicalIF":1.2000,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12903293/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Health Care and Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40780-026-00554-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Information on ceftriaxone (CTRX)-associated liver dysfunction in older patients remains limited. This study, investigated the risk factors for CTRX-associated liver dysfunction in patients aged ≥65 years.

Methods: We conducted a retrospective chart review of the medical records of 105 hospitalized patients aged ≥65 years who received CTRX at Innoshima-Ishikai Hospital. Variables significantly associated with liver dysfunction in univariate analyses were entered into a multivariate logistic regression model to identify independent risk factors. Cutoff values were determined using receiver operating characteristic curve analysis. The incidence of liver dysfunction was compared according to the number of identified risk factors. Fisher's exact test was used for comparisons between groups.

Results: In univariate analyses, alanine aminotransferase (ALT) and C-reactive protein (CRP) levels were significantly associated with liver dysfunction (p < 0.05). Multivariate logistic regression identified ALT as an independent risk factor (odds ratio [OR] 1.14; 95% confidence interval [CI]: 1.04-1.24, p = 0.003). CRP was also significantly associated with liver dysfunction, although the effect size was small (OR 1.07; 95% CI: 1.00-1.14, p = 0.043). The optimal cutoff values were 11 U/L for ALT and 5.9 mg/dL for CRP. The incidence of liver dysfunction was 0% in patients with no risk factors, 10.7% in those with elevated ALT only, 8.3% in those with elevated CRP only, and 50% in those with both elevated ALT and CRP. Patients with both risk factors had a significantly higher incidence of liver dysfunction than those in the other groups (p < 0.001).

Conclusion: Among patients aged ≥ 65 years, elevated baseline ALT (≥ 11 U/L) and CRP (≥ 5.9 mg/dL) levels were associated with an increased risk of CTRX-associated liver dysfunction. Careful monitoring of liver function during and after CTRX administration is therefore recommended in this population.

Abstract Image

Abstract Image

Abstract Image

老年患者头孢曲松相关肝功能障碍的危险因素分析。
背景:关于老年患者头孢曲松(CTRX)相关肝功能障碍的信息仍然有限。本研究调查了年龄≥65岁患者ctrx相关肝功能障碍的危险因素。方法:回顾性分析在Innoshima-Ishikai医院接受CTRX治疗的105例≥65岁住院患者的病历。在单因素分析中,与肝功能障碍显著相关的变量被纳入多因素logistic回归模型,以确定独立的危险因素。采用受试者工作特性曲线分析确定截止值。根据确定的危险因素的数量比较肝功能障碍的发生率。费雪精确检验用于组间比较。结果:在单因素分析中,丙氨酸转氨酶(ALT)和c反应蛋白(CRP)水平与肝功能障碍显著相关(p)。结论:在≥65岁的患者中,基线ALT(≥11u /L)和CRP(≥5.9 mg/dL)水平升高与ctrx相关的肝功能障碍风险增加相关。因此,建议该人群在使用CTRX期间和之后仔细监测肝功能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.80
自引率
0.00%
发文量
29
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书